Hosted on MSN9mon
Ipsen, Skyhawk enter RNA targeting research collab in rare neurological diseases
Ipsen (OTCPK:IPSEY) and Skyhawk Therapeutics Monday reported the signing of an exclusive collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases.
pharmaphorum9mon
Ipsen signs $1.8bn RNA drug alliance with Skyhawk
Ipsen has expanded its R&D pipeline once again, agreeing a $1.8 billion alliance with Skyhawk Therapeutics focused on the development of RNA-targeting therapies for rare neurological diseases.
pharmaphorum6y
Pair of deals boosts Biogen’s early-stage CNS pipeline
while Biogen is also paying Skyhawk Therapeutics $74 million upfront to license therapeutic candidates for MS, spinal muscular atrophy (SMA) and other diseases developed using its RNA platform ...
manilatimes1mon
Skyhawk Therapeutics Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington's Disease Patient Trial
BOSTON, Dec. 10, 2024 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company, today announced that the Australian Human Research Ethics Committees (HREC) have approved ...